Conference Coverage
about 2 months ago
Neoadjuvant SAbR shows promising outcomes in RCC with tumor thrombusLatest News
Feb 05, 2026 | News
Phase 1/2 trial launches of molecular glue degrader for ccRCC
FDA approves sildenafil oral film for men with erectile dysfunction
Feb 05, 2026
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
Feb 04, 2026
Pearls & Perspectives: Driving Innovation in Prosthetic Urology, with Gerard Henry, MD
Feb 04, 2026
Vanquish Water Vapor System used in first commercial prostate ablation
Feb 04, 2026
Advertisement
Shorts
1:01
Amy Luckenbaugh, MD, on advances in urologic oncology
5 hours ago
by
Amy N. Luckenbaugh, MD
4:24
World Cancer Day: Honoring Patient Resilience and Recent Advances in Urologic Oncology
a day ago
by
Hannah Clarke
1:11
Kate Kraft, MD, discusses how to build leadership presence as an introvert
a day ago
by
Kate H. Kraft, MD, MHPE, FACS, FAAP
1:02
Amanda North, MD, discusses imposter syndrome and reframing your thinking
2 days ago
by
Amanda C. North, MD
1:12
Mathew D. Sorensen, MD, MS, FACS, on how Break Wave lithotripsy works without anesthesia
3 days ago
by
Mathew D. Sorensen, MD, MS
1:07
Farah Rahman, MD, discusses wearable tech in measuring burnout
6 days ago
by
Farah Rahman, MD, MPH
1:15
Ridwan I. Alam, MD, MPH, on PHI’s role in prostate cancer risk stratification
7 days ago
by
Ridwan I. Alam, MD, MPH
1:00
Aleece Fosnight, MSPAS, PA-C, on how vaginal estrogen cream helps patients
8 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:51
The UroOnc Minute: Adam Weiner, MD, and Jeremy Teoh, MBBS, on en bloc resection of bladder tumor
9 days ago
by
Adam B. Weiner, MD(+1 more)
0:55
Sudha Jayaraman, MD, on how AI can help mitigate physician burnout
10 days ago
by
Sudha Jayaraman, MD, MSc, FACS
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
At 24 months, apalutamide demonstrated a statistically significant improvement in OS vs darolutamide without concurrent docetaxel.
Amy Pearlman, MD, sits down with Katherine A. Amin, MD, to discuss the evolving landscape of female pelvic medicine, overactive bladder management, and fellowship training.
The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
ANDROMEDA is looking to build on previous findings from the LUNAR trial in recurrent, oligometastatic prostate cancer.
The conversation highlights the steady pace of innovation in urogynecology.
Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.
In this episode, Amy Pearlman, MD, speaks with Phillip M. Pierorazio, MD, about integrating mindfulness and wellness into a demanding surgical career and the evolving complexities of modern prostate cancer care.
The combination was tolerable and demonstrated promising early efficacy as a 3rd-line option for patients with mCRPC.
Advertisement
Beyond operative technique, the episode addresses patient counseling, including expectations around fertility, anejaculation, and postoperative complications such as chyle leak.
The report highlights key trends in cancer treatment and outcomes, including detailed analyses across 3 cancer types: prostate, esophageal, and melanoma.
AVA-291 is a differentiated formulation of testosterone designed to retain androgen activity while resisting aromatization.
Gonzalgo explores how prostate cancer diagnosis and management continue to evolve.
Advertisement
Advertisement
Trending on Urology Times
1
Vanquish Water Vapor System used in first commercial prostate ablation
2
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
3
FDA approves sildenafil oral film for men with erectile dysfunction
4
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
5